FDA
-
-
-
-
-
-
-
Corvus Pharmaceuticals adds former Genentech executive to board
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
-
-
-
-
-
-
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Granted FDA Fast Track Designation for Soquelitinib
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Reports Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib
-
-
-
-
-
-
-
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

